Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 9/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 8/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580882 | 0.84 | HSP90AA1 (0.46) | PRKCQHSP90AA1PRKCDTBK1CHUK | |
| SCHEMBL4580711 | 0.82 | HSP90AA1 (0.45) | PRKCQHSP90AA1PRKCDCYP11B1CYP11B2 | |
| SCHEMBL4581754 | 0.81 | PRKCQ (0.43) | PRKCQHSP90AA1PRKCDTBK1CHUK | |
| SCHEMBL14252710 | 0.81 | PRKCQ (0.43) | PRKCQHSP90AA1PRKCDTBK1CHUK | |
| SCHEMBL4582583 | 0.80 | PRKCQ (0.44) | PRKCQHSP90AA1PRKCDCYP11B1CYP11B2 | |
| SCHEMBL4579980 | 0.80 | KDM4E (0.48) | PRKCQHSP90AA1PRKCDTBK1 | |
| SCHEMBL4579571 | 0.79 | KMT2A (0.45) | PRKCQHSP90AA1PRKCD | |
| SCHEMBL4579724 | 0.79 | PGR (0.50) | PRKCQHSP90AA1PRKCD | |
| SCHEMBL4581544 | 0.78 | PRKCQ (0.42) | PRKCQHSP90AA1PRKCDTBK1 | |
| SCHEMBL14252159 | 0.78 | PRKCQ (0.48) | PRKCQHSP90AA1PRKCDCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | PRKCQ 4430/4885HSP90AA1 3426/4885PRKCD 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.